Drug-induced switching in bipolar disorder: Epidemiology and therapeutic implications

CNS Drugs

Volumn 8, Issue 5, 1997, Pages 352-365

  Post, Robert M ^a   Denicoff, Kirk D ^a   Leverich, Gabriele S ^a   Frye, Mark A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; AMFEBUTAMONE; CARBAMAZEPINE; DESIPRAMINE; FLUOXETINE; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROXINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

DRUG EFFICACY; DRUG MIXTURE; ELECTROCONVULSIVE THERAPY; EUPHORIA; HUMAN; HYPOMANIA; MAJOR DEPRESSION; MANIC DEPRESSIVE PSYCHOSIS; MEDICAL DECISION MAKING; MOOD; PRIORITY JOURNAL; REVIEW; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 0030810191     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199708050-00002     Document Type: Review

References (80)

1. Post RM, Ketter TA, Denicoff K, et al. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology 1996; 128: 115-29
2. American Psychiatric Association. Diagnostic and statistical manual on mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994
3. Angst J. The course of affective disorders II: typology of bipolar manic-depressive illness. Arch Psychiatr Nervenkr 1978; 226: 65-74
4. Bunney Jr WE. Psychopharmacology of the switch process in affective illness. In: Lipton MA, DiMascio A, Killiam KF, editors. Psychopharmacology: a generation of progress. New York: Raven, 1978: 1249-59
5. Quitkin FM, Kane J, Rifkin A, et al. Prophylactic lithium carbonate with and without imipramine for bipolar I patients: a double-blind study. Arch Gen Psychiatry 1981; 38: 902-7
6. Prien RF, Klett CJ, Caffey Jr EM. Lithium carbonate and imipramine in prevention of affective episodes: a comparison in recurrent affective illness. Arch Gen Psychiatry 1973; 29: 420-5
7. Angst J. Switch from depression to mania - a record study over decades between 1920 and 1982. Psychopathology 1985; 18: 140-54
8. Lewis JL, Winokur G. The induction of mania: a natural history study with controls. Arch Gen Psychiatry 1982; 39: 303-6
9. Kupfer DJ, Carpenter LL, Frank F. Possible rule of antidepressants in precipitating mania and hypomania in recurrent depression. Am J Psychiatry 1988; 145: 804-8
10. Coryell W, Endicolt J, Keller M. Rapidly cycling affective disorder: demographics, diagnosis, family history, and course. Arch Gen Psychiatry 1942; 49: 126-31
11. Akiskal HS, Maser JD, Zeller PJ, et al. Switching from 'unipolar' to bipolar II: an 11-year prospective study of clinical and temperamental predictors in 559 patients. Arch Gen Psychiatry 1495; 52: 114-23
12. Bunncy Jr WE, Murphy DL, Goodwill FK, et al. The switch process from depression to mania: relationship to drugs which alter brain amines. Lancet 1970; I: 1022-6
13. Wehr TA, Goodwin FK. Rapid cycling between mania and depression caused by maintenance tricyclics. Psychopharmacol Bull 1979; 15: 17-9
14. Wehr TA, Goodwin FK. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry 1979; 36: 555-9
15. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 1987; 144: 1403-11
16. Wehr TA, Goodwill FK. Do antidepressants cause mania? Psychopharmacol Bull 1987; 23: 61-5
17. Himmelhoch JM, Thase MF, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910-6
18. Altshuler LL, Post RM, Leverich GS, et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995; 152: 1130-8
19. Rouillon F, Lejoyeux M, Filteau MJ. Unwanted effects of long-term treatment. In: Montgomery SA, Rouillon F, editors. Long-term treatment of depression. Chichester: John Wiley and Sons, 1992: 81-111
20. Squillace K, Post RM, Savard R, et al. Life charting of the longitudinal course of recurrent affective illness. In: Post RM, Ballenger JC, editors. Neurobiology of mood disorders. Baltimore: Williams and Wilkins, 1984; 38-598
21. Denicoff KD, Smith-Jackson FF, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry. In press
22. Wehr TA, Sack DA, Rosenthal NE, et al. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988; 145: 179-84
23. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium und placebo in the treatment of mania. JAM A 1994; 271: 918-24
24. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990
25. Ulrich IH, Lyons Jr MH, Guy ES. A review of lithium. W V Mod J 1980; 76: 11-5
26. Souza FG, Mander AJ, Goodwin GM. The efficacy of lithium in prophylaxis of unipolar depression: evidence from its discontinuation. Br J Psychiatry 1990; 157: 718-22
27. Frye MA, Denicoff KD, Bryan A, et al. Longitudinal assessment of thyroid function and mood stability with lithium, carbamazeptne. and combination prophylaxis in manic depressive illness [abstract]. Proceedings of the Second International Conference on Bipolar Disorder: 1997 Jun 19-21: Pittsburgh. 16
28. Wright G, Galloway L, Kim J, et al. Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects. J Clin Psychiatry 1985; 46: 22-5
29. Shopsin B. Bupropion's prophylactic efficacy in bipolar affective illness. J Clin Psychiatry 1983,44: 163-9
30. Haykal RF, Akiskal HS. Bupropion as a promising approach to rapid cycling bipolar II patients. J Clin Psychiatry 1990; 51: 450-5
31. Sachs GS, Later B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994; 55: 391-3
32. Fogelson DL, Bystritsky A, Pasnau R. Bupropion in the treatment of bipolar disorders: the same old story? J Clin Psychiatry 1992; 53: 443-6
33. Masand P, Stern TA. Bupropion and secondary mania: is there a relationship? Ann Clin Psychiatry 1993; 5: 271-4
34. Zuhieta JK, Demitrack MA. Possible hupropion precipitation of mania and a mixed affective state [letter]. J Clin Psychopharmacol 1991; II: 327
35. Kahn DA, Carpenter D, Doherty JP, et al. Expert consensus guideline series: treatment of bipolar disorder. J Clin Psychiatry 1996:57 Suppl. 12A: 1-88
36. Cohn JB, Collins G, Ashbrook E, et al. A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989; 4: 313-22
37. Boyer WE, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry 1992; 53 (2 Suppl.): 61-6
38. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164: 549-50
39. Rouillon F, Phillips R, Serrurier D, et al. Recurrence of unipolar depression and efficacy of maprotiline. Encephale 1989; 15: 527-34
40. Kramlinger KG, Post RM. The addition of lithium to carbamazepine: antidepressant efficacy in treatment-resistant depression. Arch Gen Psychiatry 1989; 46: 794-800
41. Brewerton D, Kramlinger KG, Post RM. Combination therapy with lithium and carbamazepine. In: Birch NJ, editor. Lithium: inorganic pharmacology and psychiatric use. Oxford: IRL Press, 1988: 57-60
42. Rybakowski J, Matkowski K. Adding lithium to antidepressant therapy: factors related to therapeutic potentiation. Eur Neuropsychopharmacol 1992; 2: 161-5
43. Post RM, Uhde TW, Roy-Byrne PP, et al. Antidepressant effects of carbamuzepine. Am J Psychiatry 1986; 14.3: 29-34
44. Dilsaver SC, Swann SC, Chen YW, et al. Treatment of bipolar depression with carbamazepine: results of an open study. Biol Psychiatry 1996; 40: 935-7
45. Davis LL, Kabel D, Patel D, et al. Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull 1996; 32: 647-52
46. Calabrese C. Lamotrigine in treatment refractory manic depression [abstract]. J Eur College Neuropsychopharmacol 1996; 6: 98
47. Calabrese JR, Fatemi SH, Woyshville MJ. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder |letter|. Am J Psychiatry 1996; 153: 1236
48. Frye MA, Ketter TA, Kimbrell TA, et al. Gabapentin and lamotrigine monolherapy in mood disorder [abstract no. 33C], Syllabus and Proceedings Summary of the 150th American Psychiatric Association Meeting: 1997 May 17-22; X5
49. Ferrier IN, Potkins D, Eccleston D. Lamotrigine treatment in rapid cycling bipolar disorder (BPD): clinical and biological correlates [abstract]. Proceedings of the Second International Conference on Bipolar Disorder: 1997 Jun 19-21; Pittsburgh. 15
50. Hoopes S, Snow M. Clinical effectiveness of lamotrigine in affeclive disorders [abstract]. Proceedings of Ihe Second International Conference on Bipolar Disorder: 1997 Jun 19-21: Pittsburgh, 26
51. Yatham LN, Kusumakar V. Lamotrigine in treatment of refractory bipolar depression [abstract]. Proceedings of the Second International Conference on Bipolar Disorder: 1997 Jun 19-21; Pittsburgh, 75
52. Young LT, Robb J, Patelis-Siotis I, et al. Gahapentin n bipolar depression: a case series. Biol Psychiatry. In press
53. Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50: 387-93
54. Joffe RT, Singer W. A comparison of triiodothyronine and Ihyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1991; 32: 241-51
55. Gjessing LR. Academic address: a review of periodic catatonia. Biol Psychiatry 1974; 8: 23-458
56. Slancer HC, Persad E. Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine. Arch Gen Psychiatry 1982; 39: 311-2
57. Whybrow PC. The therapeutic use of triiodothyronine and high dose thyroxine in psychiatric disorder. Acta Med Austriaca 1994; 21: 47-52
58. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990; 47: 435-40
59. Baumgurtner A, Bauer M, Hellweg R. Treatment of intractable non-rapid cycling bipolar affective disorder with high-dose thyroxine: an open clinical trial. Neuropsychopharmucology 1994; 10: 183-9
60. Frye MA, Ketter TA, Leverich G, et al. The increasing use of polypharmacy for refractory mood disorders: twenty-five years of study [abstract no. NR312]. American Psychiatric Association New Research Program and Abstracts 1996: 151-2
61. Ketter TA, Kimbrell TA, George MS, et al. Baseline hypermelabolism may predict carbamazepine response, and hypometabolism nimodipine response in mood disorders [abstract]. XXth Collegium Internationale Neuro-Psychopharmacologicum: 1996 Jun 23-27; Melbourne, 10
62. Kimbrell TA, Ketter TA, Frye MA, et al. Neuroimaging of response to new anticonvulsants [abstract no. 33D]. Syllabus and Proceedings Summary of the 150th American Psychiatric Association Meeting: 1997 May 17-22; San Diego, 85-6
63. Little JT, Ketter TA, Kimbrell TA, et al. Venlafaxine or bupropion responders but not nonresponders show haseline prefrontal and paralimbic hypometabolism compared with controls. Psychopharmacol Bull 1996; 32: 629-35
64. Calabrese JR, Woyshville MJ, Kimmel SE, et al. Predictors of valproate response in bipolar rapid cycling. J Clin Psychopharmacol 1993; 13: 280-3
65. Zis AP, Cowdry RW, Wehr TA, et al. Tricyclic-induced mania and MHPG excretion. Psychiatry Res 1979; 1: 93-9
66. Pickar D, Cowdry RW, Athanasios P, et al. Mania and hypomania during antidepressant pharmacotherapy: clinical and re- search implications. In: Post RM, Ballenger JC, editors. Neurobiology of mood disorders. Baltimore: Williams & Wilkins. 1984: 836-45
67. Post RM, Leverich GS, Pazzaglia PJ, et al. Lithium tolerance and discontinuation as pathways to refractoriness. In: Birch NJ, Padgham C, Hughes MS, editors. Lithium in medicine and biology. Carnforth: Marius Press. 1993: 71-84
68. Post RM, Leverich GS, Rosoff AS, et al. Carhamazepine prophylaxis in refractory affective disorders: a focus on longterm follow-up. J Clin Psychopharmacol 1990; 10: 318-27
69. Posl RM, Ketter TA, Pazzaglia PJ, et al. New developments in the use of anticonvulsants as mood stabilizers. Neuropsychobiology 1993; 27: 132-7
70. Pazzaglia PJ, Post RM. Contingent tolerance and reresponse to carhamazepine: a case study in a patient with trigeminal neuralgia and bipolar disorder. J Neuropsychiatry Clin Neurosci 1992; 4: 76-81
71. Weiss SRB, Clark M, Rosen JB, et al. Contingent tolerance to the anticonvulsant effects of carbamazepine: relationship to loss of endogenous mechanisms. Brain Res Rev 1995; 20: 305-25
72. Post RM, Leverich GS, Altshuler L, et al. Lithium discontinuation-induced refractoriness: preliminary observations. Am J Psychiatry 1992; 149: 1727-9
73. Koukopoulos A, Reginaldi D, Minnai G, et al. The long term prophylaxis of affective disorders. Adv Biochem Psychopharmacol 1995; 49: 127-47
74. Maj M, Pirozzi R, Magliano L. Nonresponse to reinstituted lithium prophylaxis in previously responsive bipolar patients: prevalence and predictors. Am J Psychiatry 1995; 152: 1810-1
75. Faedda GL, Tondo L, Baidessarini RJ, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch General Psychiatry 1993; 50: 448-55
76. Berghofer A, Muller-Oerlinghausen B. In: Gallicchto VS, Birch NJ, editors. Lithium: biochemical and clinical advances. Cheshire: Weidner Publishing Group. 1996: 39-46
77. Post RM, Weiss SRB. The neurobiology of treatment-resistant mood disorders. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press. 1995: 1155-70
78. Post RM, Weiss SRB. A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. Mol Neurobiology 1996; 13: 33-60
79. George MS, Wassermann EM, Williams WA, et al. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport 1995; 6: 1853-6
80. Pascual-Leone A, Rubio B, Pallardo R, et al. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet 1996; 348: 233-7